Abstract Background Evidence regarding the association of social determinants of health (SDOH) with treatment failure (TF) in uncomplicated urinary tract infection (uUTI) is lacking. This study assessed the impact of specific SDOH (including healthcare access and geographic location) on TF in patients (pts) with uUTI. Methods Female pts aged ≥ 12 years with uUTI diagnosis (Dx) between Jan 2021 and Dec 2022, excluding complicated UTI, were assessed using Inovalon’s Medical Outcomes Research for Effectiveness and Economics (MORE2) Registry (commercial, Medicare Advantage, and managed Medicaid lives) and Centers for Medicare ± 5 days of uUTI Dx). Univariate comparisons between TF and no-TF cohorts were done using Z-tests for proportions and t-tests for means. Results Overall, 1,371,784 female pts with uUTI were identified (19.1%, n=262,132 in TF cohort). The TF cohort was older than the no-TF cohort (mean median age, 50.8 50.0 vs 45.2 42.0) and had a higher percentage of Medicare FFS versus no-TF (29.6% vs 19.8%). Small absolute differences were observed between TF and no-TF cohorts across SDOH measures (Table 1) and pt characteristics (Table 2). Versus the no-TF cohort, the TF cohort exhibited higher levels of residence in rural settings and areas with full shortages in primary and mental health providers. The TF cohort also faced higher levels of food insecurity and chronic disease burden, including diabetes and obesity, as well as other SDOH factors (Table 3). Conclusion Subtle differences in SDOH between female pts with TF and no-TF for uUTI were found. Further investigation is needed to determine interactions between pt characteristics, clinical factors, and other SDOH and the impact of those interactions on TF. Funding: GSK study 222864. Disclosures Jacinda C. Abdul-Mutakabbir, PharmD, MPH, CSL Seqirus: Advisor/Consultant|CSL Seqirus: Honoraria|GSK: Advisor/Consultant|Shionogi: Advisor/Consultant|Shionogi: Honoraria Seth Kuranz, PhD, Inovalon: Employee of Inovalon, a consulting company that received funding from GSK to conduct this study. Virginia Noxon-Wood, PhD, Inovalon: Employee of Inovalon, a consulting company that received funding from GSK to conduct this study. Karl M. Kilgore, PhD, Karl M. Kilgore: Employee of Inovalon, a consulting company that received funding from GSK to conduct this study. Meghan E. Luck, PharmD, GSK: Employee|GSK: Stocks/Bonds (Public Company) Jeffrey J. Ellis, PharmD, MS, GSK: Employee|GSK: Stocks/Bonds (Public Company)
Jolla et al. (Thu,) studied this question.